Defence Therapeutics IncCanadian Securities Exchange:DTCView on Grey Market
- LAST PRICE1.4500
- TODAY'S CHANGE (%)0.1000 (7.4074%)
- Bid / Lots1.3200/ 111
- Ask / Lots1.4900/ 46
- Open / Previous Close1.3400 / 1.3500
- Day Range
- 52 Week Range
- Volume8,986
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DTC |
|---|---|---|
| 10:15 ET | 7000 | 1.45 |
Apr 17, 2024
Defence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline Growth, from 3:16AM ET on Wednesday Apr 17, 2024 by Dow Jones
3:16AM ET on Wednesday Apr 17, 2024 by Dow Jones
Apr 5, 2024
Defence Therapeutics Announces Warrant Terms Amendment, from 6:02PM ET on Friday Apr 05, 2024 by Dow Jones
6:02PM ET on Friday Apr 05, 2024 by Dow Jones
Mar 26, 2024
Defence's Successful Results on Its AccuTOX Anti-Cancer ARM Vaccine Creates a Potent Second-Generation Anti-Cancer ARM-002 Vaccine, from 3:16AM ET on Tuesday Mar 26, 2024 by Dow Jones
3:16AM ET on Tuesday Mar 26, 2024 by Dow Jones
Mar 22, 2024
Defence Completes 2nd Tranche of Financing, from 6:32PM ET on Friday Mar 22, 2024 by Dow Jones
6:32PM ET on Friday Mar 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Defence Therapeutics Inc | 61.3M | -4.6x | --- |
Briacell Therapeutics Corp | 47.1M | -2.7x | --- |
Satellos Bioscience Inc | 55.2M | -3.3x | --- |
Nurexone Biologic Inc | 39.5M | -5.3x | --- |
MustGrow Biologics Corp | 53.1M | -10.4x | --- |
KDA Group Inc | 70.1M | 209.0x | --- |
Company Information
Defence Therapeutics Inc. is a Canada-based biotechnology company working on engineering vaccines and antibody drug conjugates (ADC) products using its proprietary platform. The Company is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. Its platform's core is the Accum technology, which enables delivery of vaccine antigens or ADCs in their intact form to target cells. The Company is focused on research, development and advancement of various products using its Accum technology, which include Dendritic Cell cancer vaccines using Accum (Accuvac); a new protein-based vaccine formulation against COVID and infectious diseases; ADC targeting various cancers; anti-cancer AccuTOX program; cervical cancer vaccine; mesenchymal stromal cell-based vaccine (ARM) targeting cancer, and messenger ribonucleic acid vaccination.
Contact Information
- Headquarters
- 1680-200 Burrard StreetVANCOUVER, BC, Canada V6C 3L6
- Phone
- 514-947-2272
- Fax
- ---
Executives
- President, Chief Executive Officer, Director
- Sebastien Plouffe
- Chief Financial Officer, Director
- P. Meagher
- Vice President - Research & Development, Director
- Moutih Rafei
- Independent Director
- Kwin Grauer
- Independent Director
- Raimar Lobenberg
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $61.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 45.4M |
Defence Therapeutics Inc does not pay a dividend. | |
Beta | --- |
EPS | $-0.31 |
Book Value | $0.04 |
P/E Ratio | -4.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
